Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Kalvista Pharmaceuticals Inc (KALV)

Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Insider Sale: CHIEF EXECUTIVE OFFICER of $KALV (KALV) Sells 7,627 Shares

Benjamin L Palleiko, the CHIEF EXECUTIVE OFFICER of $KALV ($KALV), sold 7,627 shares of the company on 12-09-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

KALV : 8.36 (+3.34%)
Insider Sale: CHIEF MEDICAL OFFICER of $KALV (KALV) Sells 2,187 Shares

Paul K. Audhya, the CHIEF MEDICAL OFFICER of $KALV ($KALV), sold 2,187 shares of the company on 11-26-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 2.2%...

KALV : 8.36 (+3.34%)
Insider Sale: CHIEF DEVELOPMENT OFFICER of $KALV (KALV) Sells 1,963 Shares

Christopher Yea, the CHIEF DEVELOPMENT OFFICER of $KALV ($KALV), sold 1,963 shares of the company on 11-26-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

KALV : 8.36 (+3.34%)
DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat for the Treatment of Hereditary Angioedema Plus an Equity Investment in KalVista Pharmaceuticals

/CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the "Trust"), a global leader in providing financing to advance innovation in the life sciences...

KALV : 8.36 (+3.34%)
Jobs Report Highlighted During Holiday-Shortened Week

Monday U.S. Economic Lookahead S&P final U.S. manufacturing PMI (June) Construction ...

DDD : 3.50 (-1.41%)
DZSI : 0.7600 (unch)
PXD : 269.62 (+0.73%)
MSM : 76.77 (-0.32%)
SLP : 28.58 (-1.04%)
RDUS : 15.52 (-2.45%)
STZ : 227.63 (+0.26%)
KALV : 8.36 (+3.34%)
U.S. Inflation News Due out Next Week

Monday U.S. Featured Earnings Oracle Corporation (NYSE:ORCL) (Q1) Reported EPS of 90 cents ...

FLOW.TO : 0.1650 (+3.13%)
GRA.TO : 2.20 (+2.80%)
CXI.TO : 23.00 (unch)
ORCL : 169.66 (+0.52%)
CASY : 403.16 (-1.46%)
INNV : 4.19 (+18.70%)
EPM : 4.88 (-0.61%)
TSP : 0.2500 (-5.66%)
CBRL : 53.40 (+2.44%)
REVG : 31.78 (-1.03%)
IBEX : 20.28 (+1.30%)
ADBE : 447.17 (+2.24%)
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced...

KALV : 8.36 (+3.34%)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate...

KALV : 8.36 (+3.34%)
KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...

KALV : 8.36 (+3.34%)
KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...

KALV : 8.36 (+3.34%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar